Physician profile
Subasini Dash
NPI 1285693515
$935.24
in general payments reported to CMS, 2019-2025
25 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.63 · 2022: $81.68 · 2023: $292 · 2024: $273 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $356.25 | 2021-2024 | Austedo Xr, Austedo, Ajovy |
| Tg Therapeutics, INC. | $89.60 | 2023-2025 | |
| Ucb, INC. | $54.78 | 2024-2025 | Nayzilam, Rystiggo, Zilbrysq |
| Lundbeck LLC | $53.43 | 2024-2025 | Rexulti, Vyepti |
| Abbvie INC. | $33.60 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $32.48 | 2025 | |
| Emd Serono, INC. | $30.69 | 2022-2024 | |
| Astrazeneca Pharmaceuticals Lp | $30.07 | 2022-2025 | |
| Biogen, INC. | $27.27 | 2024 | Tysabri, Vumerity |
| Argenx US, INC. | $22.50 | 2024 | Vyvgart Hytrulo |
| Abbott Laboratories | $22.45 | 2024 | Infinity |
| Grifols USA, LLC | $19.16 | 2023 | Gamunex-C |
| Lilly USA, LLC | $19.00 | 2025 | Kisunla |
| Axsome Therapeutics, INC. | $18.30 | 2025 | Symbravo |
| Neurocrine Biosciences, INC. | $16.98 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $16.95 | 2025 | Amvuttra |
| Pfizer INC. | $16.85 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.62 | 2023 | Nuedexta |
| Celgene Corporation | $16.51 | 2024 | Zeposia |
| Xeris Pharmaceuticals, INC. | $16.17 | 2025 | Keveyis |
| Genentech USA, INC. | $14.95 | 2024 | Enspryng, Ocrevus |
| Aucta Pharmaceuticals, INC. | $10.63 | 2025 | Motpoly Xr |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subasini Dash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.